vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $205.2M, roughly 1.4× STONERIDGE INC). On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -6.0%). STONERIDGE INC produced more free cash flow last quarter ($2.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -7.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
GH vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $205.2M |
| Net Profit | $-128.5M | — |
| Gross Margin | 64.6% | 16.2% |
| Operating Margin | -43.0% | -14.4% |
| Net Margin | -45.7% | — |
| Revenue YoY | 39.4% | -6.0% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $205.2M | ||
| Q3 25 | $265.2M | $210.3M | ||
| Q2 25 | $232.1M | $228.0M | ||
| Q1 25 | $203.5M | $217.9M | ||
| Q4 24 | $201.8M | $218.2M | ||
| Q3 24 | $191.5M | $213.8M | ||
| Q2 24 | $177.2M | $237.1M | ||
| Q1 24 | $168.5M | $239.2M |
| Q4 25 | $-128.5M | — | ||
| Q3 25 | $-92.7M | $-9.4M | ||
| Q2 25 | $-99.9M | $-9.4M | ||
| Q1 25 | $-95.2M | $-7.2M | ||
| Q4 24 | $-111.0M | — | ||
| Q3 24 | $-107.8M | $-7.1M | ||
| Q2 24 | $-102.6M | $2.8M | ||
| Q1 24 | $-115.0M | $-6.1M |
| Q4 25 | 64.6% | 16.2% | ||
| Q3 25 | 64.7% | 20.3% | ||
| Q2 25 | 65.0% | 21.5% | ||
| Q1 25 | 63.3% | 21.2% | ||
| Q4 24 | 61.6% | 19.5% | ||
| Q3 24 | 61.1% | 20.8% | ||
| Q2 24 | 59.1% | 22.7% | ||
| Q1 24 | 61.2% | 20.2% |
| Q4 25 | -43.0% | -14.4% | ||
| Q3 25 | -37.3% | -1.6% | ||
| Q2 25 | -45.9% | -1.1% | ||
| Q1 25 | -54.6% | -1.5% | ||
| Q4 24 | -62.4% | -2.0% | ||
| Q3 24 | -61.3% | 0.1% | ||
| Q2 24 | -56.8% | 1.4% | ||
| Q1 24 | -59.2% | 0.1% |
| Q4 25 | -45.7% | — | ||
| Q3 25 | -35.0% | -4.5% | ||
| Q2 25 | -43.0% | -4.1% | ||
| Q1 25 | -46.8% | -3.3% | ||
| Q4 24 | -55.0% | — | ||
| Q3 24 | -56.3% | -3.3% | ||
| Q2 24 | -57.9% | 1.2% | ||
| Q1 24 | -68.2% | -2.6% |
| Q4 25 | $-1.01 | $-2.76 | ||
| Q3 25 | $-0.74 | $-0.34 | ||
| Q2 25 | $-0.80 | $-0.34 | ||
| Q1 25 | $-0.77 | $-0.26 | ||
| Q4 24 | $-0.90 | $-0.22 | ||
| Q3 24 | $-0.88 | $-0.26 | ||
| Q2 24 | $-0.84 | $0.10 | ||
| Q1 24 | $-0.94 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $66.3M |
| Total DebtLower is stronger | $1.5B | $180.9M |
| Stockholders' EquityBook value | $-99.3M | $179.8M |
| Total Assets | $2.0B | $551.2M |
| Debt / EquityLower = less leverage | — | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $66.3M | ||
| Q3 25 | $580.0M | $54.0M | ||
| Q2 25 | $629.1M | $49.8M | ||
| Q1 25 | $698.6M | $79.1M | ||
| Q4 24 | $525.5M | $71.8M | ||
| Q3 24 | $585.0M | $54.1M | ||
| Q2 24 | $933.7M | $42.1M | ||
| Q1 24 | $1.0B | $48.4M |
| Q4 25 | $1.5B | $180.9M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $179.8M | ||
| Q3 25 | $-354.5M | $251.2M | ||
| Q2 25 | $-305.5M | $260.5M | ||
| Q1 25 | $-250.8M | $253.1M | ||
| Q4 24 | $-139.6M | $245.3M | ||
| Q3 24 | $-60.1M | $271.4M | ||
| Q2 24 | $-1.6M | $270.5M | ||
| Q1 24 | $68.3M | $277.3M |
| Q4 25 | $2.0B | $551.2M | ||
| Q3 25 | $1.3B | $632.1M | ||
| Q2 25 | $1.3B | $639.4M | ||
| Q1 25 | $1.3B | $657.4M | ||
| Q4 24 | $1.5B | $621.6M | ||
| Q3 24 | $1.5B | $662.5M | ||
| Q2 24 | $1.6B | $666.7M | ||
| Q1 24 | $1.7B | $675.4M |
| Q4 25 | — | 1.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $8.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $2.6M |
| FCF MarginFCF / Revenue | -19.3% | 1.3% |
| Capex IntensityCapex / Revenue | 9.9% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $8.8M | ||
| Q3 25 | $-35.4M | $3.6M | ||
| Q2 25 | $-60.3M | $10.7M | ||
| Q1 25 | $-62.7M | $10.9M | ||
| Q4 24 | $-64.5M | $19.2M | ||
| Q3 24 | $-51.1M | $10.8M | ||
| Q2 24 | $-94.0M | $8.7M | ||
| Q1 24 | $-30.3M | $9.1M |
| Q4 25 | $-54.2M | $2.6M | ||
| Q3 25 | $-45.8M | $-2.7M | ||
| Q2 25 | $-65.9M | $7.4M | ||
| Q1 25 | $-67.1M | $4.8M | ||
| Q4 24 | $-83.4M | $14.0M | ||
| Q3 24 | $-55.3M | $4.6M | ||
| Q2 24 | $-99.1M | $1.5M | ||
| Q1 24 | $-37.2M | $3.3M |
| Q4 25 | -19.3% | 1.3% | ||
| Q3 25 | -17.3% | -1.3% | ||
| Q2 25 | -28.4% | 3.3% | ||
| Q1 25 | -33.0% | 2.2% | ||
| Q4 24 | -41.3% | 6.4% | ||
| Q3 24 | -28.9% | 2.2% | ||
| Q2 24 | -55.9% | 0.6% | ||
| Q1 24 | -22.1% | 1.4% |
| Q4 25 | 9.9% | 3.0% | ||
| Q3 25 | 3.9% | 3.0% | ||
| Q2 25 | 2.4% | 1.4% | ||
| Q1 25 | 2.2% | 2.8% | ||
| Q4 24 | 9.4% | 2.4% | ||
| Q3 24 | 2.2% | 2.9% | ||
| Q2 24 | 2.9% | 3.0% | ||
| Q1 24 | 4.1% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.11× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
